Table 5 Changes in treatment pattern by patients
|
Sunitinib 251 |
Sorafenib 62 |
Pazopanib 56 |
Everolimus 70 |
Temsirolimus 37 |
Bevacizumab 5 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Pre
143 |
Post
108 |
Pre
43 |
Post
19 |
Pre
1 |
Post
55 |
Pre
34 |
Post
36 |
Pre
19 |
Post
18 |
Pre
4 |
Post
1 | |
| Number of cycles administered | ||||||||||||
| Median (Q1–Q3) |
4.0 (2.0–5.0) |
4.0 (2.0–5.0) |
3.0 (2.0–5.0) |
3.0 (2.0–8.0) |
1.0 (1.0–1.0) |
3.0 (2.0–5.0) |
3.0 (2.0–5.0) |
4.0 (2.0–6.0) |
2.0 (1.0–4.0) |
2.5 (2.0–4.0) |
3.5 (2.5–4.5) |
10.0 (10.0–10.0) |
| *Treatment modification, n cycles (%) | ||||||||||||
| Dose reduction | 24 (16.8) | 16 (14.8) | 4 (9.3) | 1 (5.3) | 0 (0.0) | 4 (7.3) | 1 (2.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Dose interruption | 8 (5.6) | 9 (8.3) | 2 (4.7) | 2 (10.5) | 0 (0.0) | 4 (7.3) | 3 (8.8) | 4 (11.1) | 1 (5.3) | 1 (5.6) | 0 (0.0) | 0 (0.0) |
| Treatment discontinuation | 6 (4.2) | 5 (4.6) | 3 (7.0) | 0 (0.0) | 0 (0.0) | 5 (9.1) | 0 (0.0) | 3 (8.3) | 2 (10.5) | 2 (11.1) | 0 (0.0) | 0 (0.0) |
| Dose increased | 0 (0.0) | 0 (0.0) | 1 (2.3) | 2 (10.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (2.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |